Influence of exogenous factor VIIa on thrombin generation in cord plasma of full-term and pre-term newborns
- 1 June 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 11 (4) , 349-357
- https://doi.org/10.1097/00001721-200006000-00006
Abstract
Factor (F) VIIa has been used to treat adults and children with a variety of bleeding disorders. The results from these studies cannot be extrapolated to newborns because their hemostatic system differs significantly from adults, which may influence the effects of FVIIa on thrombin (IIa) generation. We compared the effects of FVIIa concentrates on IIa generation in plasmas from adults, full-term newborns and pre-term newborns. Defibrinated plasma (using arvin) from adults, or umbilical cords from full-term or pre-term deliveries was supplemented with FVIIa (Novo Nordisk, Bagsvaerd, Denmark), mixed with dilute thromboplastin reagent, and the resultant reaction mixture subsampled periodically into ethylenediamine tetraacetic acid, followed by measurement of total IIa activity (S-2238). Thrombin–α2Macroglobulin complexes, determined as residual activity after neutralization with heparin and antithrombin, were subtracted from total IIa to give free IIa. Prothrombin (FII) and inhibitor complexes were measured by enzyme-linked immunosorbent assays. Addition of FVIIa caused a reduction in the lag phase for the appearance of free IIa and consumption of FII, which was more pronounced in newborn plasma. There was no increase in peak IIa levels regardless of the amount of FVIIa added. Final inhibitor complex concentrations were increased in plasmas from adults compared with newborns, likely reflecting higher plasma concentrations of FII in adults. Generation of IIa was more rapid in pre-term plasma compared with that in adult and full-term cord plasmas due to increased endogenous tissue factor (TF). In summary, FVIIa enhanced IIa generation in plasma from different age groups, with the effect being more pronounced in plasma from pre-term newborns, possibly due to increased levels of plasma TF.Keywords
This publication has 22 references indexed in Scilit:
- A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitorsHaemophilia, 1998
- Clinical picture and treatment strategies in factor VII deficiencyHaemophilia, 1998
- CONTROL OF CEREBRAL AND OCULAR BLOOD FLOW AUTOREGULATION IN NEONATESPediatric Clinics of North America, 1997
- Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitorsAmerican Journal of Hematology, 1994
- Thrombin Inhibition Is Impaired in Plasma of Sick NeonatesPediatric Research, 1992
- A549 Lung Epithelial Cells Synthesize Anticoagulant Molecules on the Cell Surface and Matrix and in Conditioned MediaAmerican Journal of Respiratory Cell and Molecular Biology, 1991
- Development of the human coagulation system in the healthy premature infantBlood, 1988
- Development of the human coagulation system in the full-term infantBlood, 1987
- Prevention of intraventricular haemorrhage by fresh frozen plasma.Archives of Disease in Childhood, 1985
- Controlled trial of fresh frozen plasma in asphyxiated low birthweight infantsArchives of Disease in Childhood, 1973